Report of Foreign Issuer (6-k)
26 March 2019 - 11:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of
1934
For the month of March, 2019
Commission File Number 001-38522
Realm Therapeutics plc
(Translation of registrant’s name
into English)
267 Great Valley Parkway
Malvern, PA 19355
(Address of principal executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT
ON FORM 6-K
On March 26, 2019, Realm Therapeutics plc
(the “Company”) announced on March 15, 2019 that the Company’s AIM listing will cease and cancellation will be
effective from 7:00 a.m. (GMT) on March 27, 2019.
Accordingly, today will be the last day
of trading of Realm’s Ordinary Shares on AIM. Information on how to convert Ordinary Shares to American Depositary Shares
(“ADSs”) is available on the Company’s website at www.realmtx.com.
With effect from March 27, 2019, on the
basis that the Company’s place of central management and control is outside of the UK, Channel Islands and the Isle of Man,
whilst the sale process continues, the Takeover Code will no longer apply to the Company and the process will no longer be a “formal
process” under the Takeover Code.
Capitalized terms used but not defined
in this announcement shall have the meanings given to them in the circular sent to Realm shareholders on 15 February 2019, which
remains available on the Company’s website at www.realmtx.com.
The Exhibit to this Report on Form 6-K
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any
filing of the Company under the Securities Act of 1933 or the Exchange Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Realm Therapeutics plc
|
|
|
|
|
|
|
March 26, 2019
|
|
|
|
By:
|
|
/s/ Marella Thorell
|
|
|
|
|
|
|
|
Marella Thorell
|
|
|
|
|
|
|
|
Chief Financial Officer and Chief Operating Officer
|
Realm Therapeutics (NASDAQ:RLM)
Historical Stock Chart
From May 2024 to Jun 2024
Realm Therapeutics (NASDAQ:RLM)
Historical Stock Chart
From Jun 2023 to Jun 2024
